Article citationsMore >>

Lorenzo-Zúñiga V, Llop E, Suárez C, Álvarez B, Abreu L, Espadaler J, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014 Jul 14; 20(26): 8709-16.

has been cited by the following article:


Meta-Analysis Study the Role of Probiotics Treatment in Irritable Bowel Syndrome (1990-2017)

1Seremban Prison, Malaysian Prison Department, Home Ministry, Malaysia

2Department of Post-Graduate Studies, Perdana University, Malaysia

3SP Care Group, Health Care, Malaysia

4Department of Rehabilitation Medicine, Hospital Tunku Ampuan Rahimah, Ministry of Health, Malaysia

5Child Health Department, Sabak Bernam District Health Department, Ministry of Health, Malaysia

6Klinik Sri Pulai Sdn Bhd

Journal of Food and Nutrition Research. 2018, Vol. 6 No. 11, 710-718
DOI: 10.12691/jfnr-6-11-6
Copyright © 2018 Science and Education Publishing

Cite this paper:
Selvaganapathi G., Jinat Ahmed J.A., Mathialagan AG, Dinesh M., Azra N., Harikrishnan T., Kohila J.R., Fathy I., Ramalinggam R., Tee HY, Vanita S.. Meta-Analysis Study the Role of Probiotics Treatment in Irritable Bowel Syndrome (1990-2017). Journal of Food and Nutrition Research. 2018; 6(11):710-718. doi: 10.12691/jfnr-6-11-6.

Correspondence to: Jinat  Ahmed J.A., Department of Post-Graduate Studies, Perdana University, Malaysia. Email:


Objective: To examine the relationship between Probiotics and its efficacy in reducing the symptoms of Irritable Bowel Syndrome (IBS). Methods: A meta-analysis was conducted to evaluate the quality of the clinical trials and evidence with respect to the efficacy of probiotics for the treatment of IBS. Medline, PubMed, Google Scholar, NIH registry of clinical trials, and Cochrane Central Register of Controlled Trials were reviewed from the year 1990-2017 to identify studies that fulfilled inclusion criteria and exclusion criteria. Findings: 1650 studies were found on probiotics use in IBS. From that, only 70 studies fulfilled inclusion and exclusion criteria that were defined for this study. After assessment with Linde Internal Validity Scale, around 18 clinical trials were identified for data extraction. From those studies, it was seen that probiotic use was associated with improvement in global IBS symptoms compared to placebo [pooled relative risk (RRpooled) 0.77, 95% confidence interval (95% CI) 0.62-0.94]. Probiotics were also associated with less abdominal pain compared to placebo [RRpooled = 0.78 (0.69-0.88)]. Of the 11 species and species mixtures, Lactobacillus rhamnosus GG was the most frequent tested probiotics. None of the 18 trials reported any serious adverse events with probiotic use. Conclusion: For management of IBS, probiotics were significantly more protective and effective than placebo.